Today's Daily Dose brings you news about inclusion of Evelo's EDP1815 in COVID-19 trial; analyst upgrade of Five Prime; Gilead's plan to test inhaled version of experimental antiviral medicine Remdesivir; Hepion's efficacy of NASH drug candidate in mouse models of renal fibrosis; Invitae's acquisition of ArcherDX for about $1.4 billion and expanded approval of Karyopharm's Xpovio.
from RTT - Biotech https://ift.tt/2V9IXiB
via IFTTT
No comments:
Post a Comment